PPADS tetrasodium salt | CAS#192575-19-2 | P2 receptor antagonist

MedKoo Cat#: 527813 | Name: PPADS tetrasodium salt

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PPADS tetrasodium salt is a P2 receptor antagonist.

Chemical Structure

PPADS tetrasodium salt

CAS#192575-19-2

Theoretical Analysis

MedKoo Cat#: 527813

Name: PPADS tetrasodium salt

CAS#: 192575-19-2

Chemical Formula: C14H10N3Na4O12PS2

Exact Mass: 598.9034

Molecular Weight: 599.30

Elemental Analysis: C, 28.06; H, 1.68; N, 7.01; Na, 15.34; O, 32.04; P, 5.17; S, 10.70

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 230.00
50mg	USD 550.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

PPADS tetrasodium salt; PPADS (4Na) ; PPADS (tetrasodium)

IUPAC/Chemical Name

4-[[4-Formyl-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]-2-pyridinyl]azo]-1,3-benzenedisulfonic acid tetrasodium salt

InChi Key

KURWUCJJNVPCHT-PGXCWKBOSA-J

InChi Code

InChI=1S/C14H14N3O12PS2.4Na/c1-7-13(19)9(5-18)10(6-29-30(20,21)22)14(15-7)17-16-11-3-2-8(31(23,24)25)4-12(11)32(26,27)28;;;;/h2-5,19H,6H2,1H3,(H2,20,21,22)(H,23,24,25)(H,26,27,28);;;;/q;4*+1/p-4/b17-16+;;;;

SMILES Code

O=S(C1=CC=C(/N=N/C2=NC(C)=C(O)C(C=O)=C2COP([O-])([O-])=O)C(S(=O)([O-])=O)=C1)([O-])=O.[Na+].[Na+].[Na+].[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

PPADS tetrasodiuma is a non-selective P2X receptor antagonist.

In vitro activity:

This study found that PPADS, a P2X receptor antagonist, acts as a NCX(REV) inhibitor in guinea pig tracheal myocytes. To evaluate the effect of different NCX(REV) blockers, concentration response curves to KB-R7943 (1, 3.2 and 10 μM), and SN-6 (3.2, 10 and 30 μM) were constructed, whereas PPADS effect was characterized as time- and concentration-dependent (1, 3.2, 10 and 30 μM). PPADS had similar potency and efficacy as KB-R7943, whereas SN-6 was the least effective. Furthermore, KCl-induced contraction, sensitive to D600 and nifedipine, was blocked by KB-R7943, but not by PPADS. KCl-induced [Ca(2+)]i increment in myocytes was also significantly decreased by KBR-7943 (10 μM). Our results demonstrate that PPADS can be used as a reliable pharmacological tool to inhibit NCX(REV), with the advantage that it is more specific than KB-R7943 because it does not affect L-type Ca(2+) channels. Reference: Eur J Pharmacol. 2012 Jan 15;674(2-3):439-44. https://pubmed.ncbi.nlm.nih.gov/22119380/

In vivo activity:

alpha,beta-MeATP (0.1-100 microM) caused concentration-dependent contractions of the rabbit ear and saphenous arteries. The negative log[alpha,beta-MeATP] that produced a contraction equivalent to the EC25 for noradrenaline (ear artery) or histamine (saphenous artery) in the absence of PPADS was 6.60 +/- 0.18 (9) and 6.18 +/- 0.17 (9) in the ear artery and saphenous artery, respectively. These effects of exogenous alpha,beta-MeATP were concentration-dependently inhibited by PPADS (1-30 microM). In the ear artery, the negative log[alpha,beta-MeATP] producing a contractile response equivalent to the EC25 of noradrenaline, in the presence of PPADS at 1, 3 and 10 microM was 6.16 +/- 0.18 (8), 5.90 +/- 0.18 (8) and 4.72 +/- 0.36 (8), respectively (P < 0.01). In the saphenous artery, the negative log[alpha,beta-MeATP] values equivalent to the EC25 for histamine in the presence of PPADS at concentrations of 1, 3, 10 and 30 microM were 5.90 +/- 0.19 (8), 5.73 +/- 0.16 (8), 4.99 +/- 0.14 (8) and 4.51 +/- 0.13 (8), respectively (P < 0.01). Reference: Br J Pharmacol. 1994 Mar;111(3):923-9. https://pubmed.ncbi.nlm.nih.gov/8019770/

	Solvent	mg/mL	mM	comments
Solubility
	Water	50.0	83.43

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 599.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Flores-Soto E, Reyes-García J, Sommer B, Chavez J, Barajas-López C, Montaño LM. PPADS, a P2X receptor antagonist, as a novel inhibitor of the reverse mode of the Na⁺/Ca²⁺ exchanger in guinea pig airway smooth muscle. Eur J Pharmacol. 2012 Jan 15;674(2-3):439-44. doi: 10.1016/j.ejphar.2011.11.018. Epub 2011 Nov 19. PMID: 22119380. 2. McLaren GJ, Lambrecht G, Mutschler E, Bäumert HG, Sneddon P, Kennedy C. Investigation of the actions of PPADS, a novel P2x-purinoceptor antagonist, in the guinea-pig isolated vas deferens. Br J Pharmacol. 1994 Mar;111(3):913-7. doi: 10.1111/j.1476-5381.1994.tb14825.x. PMID: 8019769; PMCID: PMC1910078. 3. Rost S, Daniel C, Schulze-Lohoff E, Bäumert HG, Lambrecht G, Hugo C. P2 receptor antagonist PPADS inhibits mesangial cell proliferation in experimental mesangial proliferative glomerulonephritis. Kidney Int. 2002 Nov;62(5):1659-71. doi: 10.1046/j.1523-1755.2002.00621.x. PMID: 12371966. 4. Ziganshin AU, Hoyle CH, Lambrecht G, Mutschler E, Bümert HG, Burnstock G. Selective antagonism by PPADS at P2X-purinoceptors in rabbit isolated blood vessels. Br J Pharmacol. 1994 Mar;111(3):923-9. doi: 10.1111/j.1476-5381.1994.tb14827.x. PMID: 8019770; PMCID: PMC1910106.

In vitro protocol:

In vivo protocol:

1. Rost S, Daniel C, Schulze-Lohoff E, Bäumert HG, Lambrecht G, Hugo C. P2 receptor antagonist PPADS inhibits mesangial cell proliferation in experimental mesangial proliferative glomerulonephritis. Kidney Int. 2002 Nov;62(5):1659-71. doi: 10.1046/j.1523-1755.2002.00621.x. PMID: 12371966. 2. Ziganshin AU, Hoyle CH, Lambrecht G, Mutschler E, Bümert HG, Burnstock G. Selective antagonism by PPADS at P2X-purinoceptors in rabbit isolated blood vessels. Br J Pharmacol. 1994 Mar;111(3):923-9. doi: 10.1111/j.1476-5381.1994.tb14827.x. PMID: 8019770; PMCID: PMC1910106.

1: Ferreira-Neto HC, Antunes VR, Stern JE. ATP stimulates rat hypothalamic sympathetic neurons by enhancing AMPA receptor-mediated currents. J Neurophysiol. 2015 Jul;114(1):159-69. doi: 10.1152/jn.01011.2014. Epub 2015 Apr 22. PubMed PMID: 25904713; PubMed Central PMCID: PMC4507951. 2: Ibusuki K, Sakiyama T, Kanmura S, Maeda T, Iwashita Y, Nasu Y, Sasaki F, Taguchi H, Hashimoto S, Numata M, Uto H, Tsubouchi H, Ido A. Human neutrophil peptides induce interleukin-8 in intestinal epithelial cells through the P2 receptor and ERK1/2 signaling pathways. Int J Mol Med. 2015 Jun;35(6):1603-9. doi: 10.3892/ijmm.2015.2156. Epub 2015 Mar 26. PubMed PMID: 25816245. 3: Ren H, Teng Y, Tan B, Zhang X, Jiang W, Liu M, Jiang W, Du B, Qian M. Toll-like receptor-triggered calcium mobilization protects mice against bacterial infection through extracellular ATP release. Infect Immun. 2014 Dec;82(12):5076-85. doi: 10.1128/IAI.02546-14. Epub 2014 Sep 22. PubMed PMID: 25245808; PubMed Central PMCID: PMC4249268. 4: Jitprasertwong P, Jaedicke KM, Nile CJ, Preshaw PM, Taylor JJ. Leptin enhances the secretion of interleukin (IL)-18, but not IL-1β, from human monocytes via activation of caspase-1. Cytokine. 2014 Feb;65(2):222-30. doi: 10.1016/j.cyto.2013.10.008. Epub 2013 Nov 23. PubMed PMID: 24275551. 5: Gibbs ME, Shleper M, Mustafa T, Burnstock G, Bowser DN. ATP derived from astrocytes modulates memory in the chick. Neuron Glia Biol. 2011 May;7(2-4):177-86. doi: 10.1017/S1740925X12000117. Epub 2012 Jul 6. PubMed PMID: 22874656. 6: Vavra V, Bhattacharya A, Zemkova H. Facilitation of glutamate and GABA release by P2X receptor activation in supraoptic neurons from freshly isolated rat brain slices. Neuroscience. 2011 Aug 11;188:1-12. doi: 10.1016/j.neuroscience.2011.04.067. Epub 2011 May 7. PubMed PMID: 21575687. 7: Yang J, Ip PS, Yeung JH, Che CT. Inhibitory effect of schisandrin on spontaneous contraction of isolated rat colon. Phytomedicine. 2011 Aug 15;18(11):998-1005. doi: 10.1016/j.phymed.2011.02.014. Epub 2011 Apr 21. PubMed PMID: 21514126; PubMed Central PMCID: PMC3159731. 8: Wu T, Dai M, Shi XR, Jiang ZG, Nuttall AL. Functional expression of P2X4 receptor in capillary endothelial cells of the cochlear spiral ligament and its role in regulating the capillary diameter. Am J Physiol Heart Circ Physiol. 2011 Jul;301(1):H69-78. doi: 10.1152/ajpheart.01035.2010. Epub 2011 Apr 1. PubMed PMID: 21460192; PubMed Central PMCID: PMC3129919. 9: Yoshida A, Kageyama A, Fujino T, Nozawa Y, Yamada S. Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis. Urology. 2010 Oct;76(4):1017.e7-12. doi: 10.1016/j.urology.2010.05.012. Epub 2010 Aug 16. PubMed PMID: 20719367. 10: Gulbransen BD, Sharkey KA. Purinergic neuron-to-glia signaling in the enteric nervous system. Gastroenterology. 2009 Apr;136(4):1349-58. doi: 10.1053/j.gastro.2008.12.058. Epub 2009 Jan 1. PubMed PMID: 19250649. 11: Kageyama A, Fujino T, Taki Y, Kato Y, Nozawa Y, Ito Y, Yamada S. Alteration of muscarinic and purinergic receptors in urinary bladder of rats with cyclophosphamide-induced interstitial cystitis. Neurosci Lett. 2008 May 2;436(1):81-4. doi: 10.1016/j.neulet.2008.02.065. Epub 2008 Mar 5. PubMed PMID: 18372110. 12: Zizzo MG, Mulè F, Serio R. Inhibitory purinergic transmission in mouse caecum: role for P2Y1 receptors as prejunctional modulators of ATP release. Neuroscience. 2007 Dec 12;150(3):658-64. Epub 2007 Sep 29. PubMed PMID: 17997228. 13: De Lorenzo S, Veggetti M, Muchnik S, Losavio A. Presynaptic inhibition of spontaneous acetylcholine release mediated by P2Y receptors at the mouse neuromuscular junction. Neuroscience. 2006 Sep 29;142(1):71-85. Epub 2006 Jul 14. PubMed PMID: 16843602. 14: Wollmann G, Acuna-Goycolea C, van den Pol AN. Direct excitation of hypocretin/orexin cells by extracellular ATP at P2X receptors. J Neurophysiol. 2005 Sep;94(3):2195-206. Epub 2005 Jun 15. PubMed PMID: 15958604. 15: Zhao D, Ren LM. Non-adrenergic inhibition at prejunctional sites by agmatine of purinergic vasoconstriction in rabbit saphenous artery. Neuropharmacology. 2005 Mar;48(4):597-606. PubMed PMID: 15755487. 16: Lin Y, Desbois A, Jiang S, Hou ST. P2 receptor antagonist PPADS confers neuroprotection against glutamate/NMDA toxicity. Neurosci Lett. 2005 Mar 29;377(2):97-100. Epub 2004 Dec 19. PubMed PMID: 15740844. 17: Paton JF, De Paula PM, Spyer KM, Machado BH, Boscan P. Sensory afferent selective role of P2 receptors in the nucleus tractus solitarii for mediating the cardiac component of the peripheral chemoreceptor reflex in rats. J Physiol. 2002 Sep 15;543(Pt 3):995-1005. PubMed PMID: 12231653; PubMed Central PMCID: PMC2290539. 18: Ren LM, Burnstock G. Prominent sympathetic purinergic vasoconstriction in the rabbit splenic artery: potentiation by 2,2'-pyridylisatogen tosylate. Br J Pharmacol. 1997 Feb;120(3):530-6. PubMed PMID: 9031760; PubMed Central PMCID: PMC1564488.